Search results for "Alcoholic"

showing 10 items of 509 documents

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

2017

Background & Aims Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 ± 14; body mass index 27.2 ± 5.3 kg/m2). The primary outco…

AdultMalemedicine.medical_specialtyBiopsyAutoimmune hepatitisHepatic steatosiDiagnostic accuracyGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineNonalcoholic fatty liver diseaseMedicineHumansLiver stiffness measurementAgedFibroScanHepatologymedicine.diagnostic_testbusiness.industryFatty liverReproducibility of ResultsLiver biopsyHepatologyMiddle Agedmedicine.diseaseFatty LiverCross-Sectional StudiesLiverROC Curve030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisTransient elastographybusinessNon-alcoholic fatty liver diseaseJournal of hepatology
researchProduct

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

2018

Background & Aims: Transient elastography (TE) is a noninvasive technique used to measure liver stiffness to estimate the severity of fibrosis. The range of liver stiffness measurements (LSMs) in healthy individuals is unclear. We performed a systematic review to determine the range of LSMs, examined by TE, in healthy individuals and individuals who are susceptible to fibrosis. Methods: We collected data from 16,082 individuals, in 26 cohorts, identified from systematic searches of Embase, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for studies of liver stiffness measurements. Studies analyzed included apparently healthy adul…

AdultMalemedicine.medical_specialtyCirrhosisAdolescent03 medical and health sciencesYoung AdultBMI0302 clinical medicineInternal medicineDiabetes mellitusNonalcoholic fatty liver diseasemedicineHumansObesityAgedAged 80 and overCirrhosiAnthropometryHepatologybusiness.industryGastroenterologyBMI; Cirrhosis; Fibroscan; Obesity; Hepatology; GastroenterologyMiddle Agedmedicine.diseaseElasticityHealthy VolunteersFibroscanLiver030220 oncology & carcinogenesisCohortElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleMetabolic syndromeTransient elastographybusinessBody mass indexDyslipidemiaClinical Gastroenterology and Hepatology
researchProduct

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct

Reducing NAFLD-screening time: A comparative study of eight diagnostic methods offering an alternative to ultrasound scans.

2018

Background & Aims: The use of ultrasound scan (US) in non-alcoholic fatty liver disease (NAFLD) screening overloads US waiting lists. We hypothesized and tested a hybrid two-step method, consisting of applying a formula, to exclude subjects at low risk, before US. Methods: The sample included 2970 males and females (937 with NAFLD) diagnosed by US. We selected eight formulas: Fatty Liver Index (FLI), Hepatic Steatosis Index (HIS), body mass index (BMI), waist circumference (WC), Abdominal Volume Index (AVI), waist-to-height ratio (WHtR), waist/height0.5 (WHT.5R) and Body Roundness Index (BRI), and calculated their performance in the two-step method evaluating percentage reduction of the…

AdultMalemedicine.medical_specialtyDiagnostic methodsWaistGastroenterologyBody Mass Index03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineScreening methodMedicineHumansAgedUltrasonographyHepatologyAnthropometrybusiness.industryWaist-Hip RatioFatty liverUltrasoundnutritional and metabolic diseasesPercentage reductionMiddle Agedmedicine.diseasescreening NAFLDItalyROC Curve030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSteatosisWaist CircumferencebusinessBody mass indexLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis

2015

Aim Non-alcoholic fatty liver disease (NAFLD) is commonly associated with Type 2 diabetes. Recently, it has been suggested that NAFLD is also frequently associated with Type 1 diabetes and diabetic complications. In this study, we set out to determine whether Type 1 diabetes was associated with liver fat content measured using magnetic resonance imaging. Methods One hundred and twenty-eight patients with Type 1 diabetes, 264 patients with Type 2 diabetes and 67 participants without diabetes were included in this study. Hepatic steatosis was defined as a liver fat content > 5.5%. Results People with Type 1 diabetes and controls were similar for age and BMI. Liver fat content was significantl…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismGastroenterologyBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineDiabetes mellitusPrevalenceInternal MedicineHumansMass ScreeningMedicineObesityProspective StudiesProspective cohort studyMass screeningAgedType 1 diabetesbusiness.industryFatty liverAge FactorsMiddle AgedOverweightmedicine.diseaseMagnetic Resonance ImagingDiabetes Mellitus Type 1Diabetes Mellitus Type 2LiverIntima-media thicknessFemaleFranceSteatosisbusinessBody mass indexDiabetic Medicine
researchProduct

Fatty liver and mortality: a cohort population study in South Italy

2019

ObjectiveAlcoholic fatty liver (AFLD) and non-alcoholic fatty liver (NAFLD) are two common conditions. However, if they can increase the risk of death is poorly explored. We therefore aimed to investigate the potential association between the presence and severity of liver steatosis and mortality in a large sample of older people.DesignProspective.SettingCommunity.ParticipantsWomen and men randomly sampled from the electoral rolls of the population of Castellana Grotte, a town in Southern Italy (Apulia region) between 2005 and 2006. Among 1942 initially contacted, 1708 (=87.9%) participated to the baseline survey (Multicentrica Colelitiasi III (MICOL III)). This specific study included 1445…

AdultMalemedicine.medical_specialtyEpidemiologyPopulationhepatobiliary disease03 medical and health sciences0302 clinical medicineRisk FactorsCause of DeathInternal medicineHumansMedicine1506Prospective StudiesRisk factoreducationgeneral endocrinologyAgedAged 80 and overeducation.field_of_studybusiness.industryResearchFatty liverHepatobiliary diseaseGeneral MedicineMiddle Agedmedicine.diseasemortality1692Fatty LiverSurvival RateItalyPopulation Surveillance030220 oncology & carcinogenesisCohortPopulation studyFemale030211 gastroenterology & hepatologyAlcoholic fatty liverSteatosisbusinessBMJ Open
researchProduct

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1.

2008

Retinol-binding protein 4 (RBP4) is an adipocytokine associated with insulin resistance (IR). We tested serum levels of RBP4 to assess its link with steatosis in patients with genotype 1 chronic hepatitis C (CHC) or nonalcoholic fatty liver disease (NAFLD). Nondiabetic patients with CHC (n = 143) or NAFLD (n = 37) were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR by the homeostasis model assessment. Biopsies were scored by Scheuer classification for CHC, and Kleiner for NAFLD. Steatosis was tested as a continuous variable and graded as absent-mild <30%, or moderate-severe > or =30%. Thirty nondiabetic, nonobese blood donors served as controls. …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologySeverity of Illness IndexInsulin resistanceRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicinesteatosisHumansRetinol-binding protein 4 .Retinol binding protein 4Settore MED/12 - GastroenterologiaHepatologybiologymedicine.diagnostic_testOdds ratioHepatologyHepatitis C ChronicMiddle Agedmedicine.diseaseFatty LiverLogistic ModelsLiverLiver biopsyImmunologybiology.proteinFemaleSteatosisRetinol-Binding Proteins PlasmaBiomarkers
researchProduct

The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis

2015

Background & Aims Uncoupling protein 2 - UCP2 - regulates mitochondrial lipid fluxes and reactive oxygen species production by the respiratory chain. The −866 G>A UCP2 promoter region polymorphism has been linked to insulin resistance and lipid metabolism. The aim of this study was to assess whether the −866 G>A UCP2 polymorphism predisposes to nonalcoholic steatohepatitis in patients at risk, and the relationship with lipid metabolism and hepatic UCP2 expression. Methods We considered 688 Italian patients who underwent liver biopsy for suspected NASH, and 232 healthy controls. The UCP2 −866 G>A polymorphism was determined by allele specific oligonucleotide probes, hepatic UCP2 mRNA levels …

AdultMalemedicine.medical_specialtyGenotypeRespiratory chainGene ExpressionBiologyIon ChannelsMitochondrial Proteinsgenetic polymorphism; lipid metabolism;liver; mitochondria; nonalcoholic steatohepatitis; uncoupling protein-2Insulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsDiabetes mellitusInternal medicineGenotypemedicineHumansUncoupling Protein 2Promoter Regions GeneticUncoupling protein-2AllelesAgedPolymorphism GeneticGenetic polymorphismmedicine.diagnostic_testHepatologyLipid metabolismMiddle Agedmedicine.diseaseImpaired fasting glucoseMitochondriaEndocrinologyLogistic ModelsLipid metabolismLiverLiver biopsyCase-Control StudiesFemaleSteatosisInsulin ResistanceNonalcoholic steatohepatiti
researchProduct

Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease.

2013

Backgrounds & Aims: Healthy diet and physical activity are the treatment cornerstones of non-alcoholic fatty liver disease (NAFLD); their effectiveness is however limited by difficulties in implementing lifestyle changes. We aimed at determining the stage of change and associated psychological factors as a prerequisite to refine strategies to implement behavior changes. Methods: We studied 138 consecutive NAFLD patients (73% male, age 19-73 years). The diagnosis was confirmed by liver biopsy in 64 cases (steatohepatitis, 47%). All cases completed the validated EMME-3 questionnaire, consisting of two parallel sets of instruments (for diet and physical activity, respectively) and providing st…

AdultMalemedicine.medical_specialtyHealth BehaviorDiseaseMotor ActivityLogistic regressionPsychological factorsDIETNAFLD. LIFESTYLEYoung Adult03 medical and health sciencesWEIGHT LOSS0302 clinical medicineHumansNON-ALCOHOLIC FATTY LIVER DISEASEMedicine030212 general & internal medicineYoung adultLife StyleAgedHepatologybusiness.industryPhysical activityBehavior changeFatty liverTranstheoretical modelLIFESTYLE DETERMINANTSMOTIVATIONOdds ratioMiddle Agedmedicine.diseaseLifestyle3. Good healthFatty LiverHealthy dietPhysical therapyFemale030211 gastroenterology & hepatologysense organsSteatohepatitisbusinessDemography
researchProduct

Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome

2010

NASH (non-alcoholic steatohepatitis) is considered the hepatic manifestation of the metabolic syndrome (MS). We aimed to analyze lipid, carbohydrate, and iron metabolism in NASH.37 patients with MS (17 M/20 F, 51+/-15 years), elevated transaminases; 25 patients had histologically proven NASH (NAS score≥5), 12 patients had toxic background (nonNASH). 37 age, sex, BMI-matched healthy controls. Lipid variables, LDL-subfractions, iron, ferritin, transferrin (T), transferrin saturation (TS), and hepcidin (H) were measured in patients/controls. Oral glucose tolerance tests were performed.NASH patients with steatosis gr. 2 and 3 (33% hepatic fat) had higher sd-LDL (mg/dl) concentrations than patie…

AdultMalemedicine.medical_specialtyIronInsulin resistanceHepcidinsNon-alcoholic Fatty Liver DiseaseInternal medicineInternal MedicinemedicineHumansInsulinAgedMetabolic Syndromechemistry.chemical_classificationGlucose tolerance testC-Peptidemedicine.diagnostic_testTransferrin saturationbusiness.industryTransferrinnutritional and metabolic diseasesLipid metabolismCholesterol LDLGlucose Tolerance TestMiddle AgedLipid Metabolismmedicine.diseasedigestive system diseasesFatty LiverEndocrinologychemistryTransferrinFerritinsMetabolomeCarbohydrate MetabolismFemaleMetabolic syndromeSteatosisSteatohepatitisbusinessAntimicrobial Cationic PeptidesEuropean Journal of Internal Medicine
researchProduct